-
Mashup Score: 2MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC - 11 month(s) ago
MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 5Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer - 11 month(s) ago
Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer #pancsm #oncology https://t.co/BiPKCj7Qj2
-
-
Mashup Score: 1
XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer #pancsm #oncology https://t.co/I31HESBfHF
-
-
Mashup Score: 1
XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer #pancsm #oncology https://t.co/I31HESBfHF
-
-
Mashup Score: 1
XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer #pancsm #oncology https://t.co/I31HESBfHF
-
-
Mashup Score: 2
XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer #pancsm #oncology https://t.co/I31HESBfHF
-
-
Mashup Score: 2MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC - 12 month(s) ago
MPO may be a predictive biomarker for survival for treatment with CM24, nivolumab, and chemotherapy in second-line pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC #pancsm #oncology https://t.co/zdqMj7NrrU
-
-
Mashup Score: 4Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer - 12 month(s) ago
Frontline mitazalimab plus mFOLFIRINOX generated an OS benefit and prolonged DOR in patients with metastatic pancreatic ductal adenocarcinoma.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Mitazalimab Plus mFOLFIRINOX Yields 18-Month OS Benefit in Previously Untreated Metastatic Pancreatic Cancer #pancsm #oncology https://t.co/BiPKCj7Qj2
-
-
Mashup Score: 1
XB2001 plus chemotherapy improved safety and was tied to a trend toward improved overall survival in pretreated advanced pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
Addition of XB2001 to Chemo Improves Safety in Advanced Pancreatic Cancer #pancsm #oncology https://t.co/I31HESBfHF
-
-
Mashup Score: 3CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer - 1 year(s) ago
CT041 was safe and showcased early signals of antitumor activity in heavily pretreated patients with metastatic pancreatic cancer.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet-
CT041 Shows Tolerability and Early Efficacy in Refractory Metastatic Pancreatic Cancer #pancsm #oncology https://t.co/VpRcrwH8H2
-
MPO Could Represent Predictive OS Biomarker for CM24 Plus Nivolumab/Chemo in Second-Line PDAC #pancsm #oncology https://t.co/zdqMj7NrrU